- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00799864
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
August 14, 2023 updated by: Janssen Sciences Ireland UC
A Phase II, Open Label, Single Arm Trial to Evaluate the Pharmacokinetics,Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral Naive HIV-1 Infected Adolescents and Children Aged >= 6 to <18 Years
The purpose of this study is to evaluate the pharmacokinetics, safety and antiviral activity of rilpivirine (TMC278) 25 milligram (mg) or adjusted dose once daily in combination with an investigator-selected background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs) (zidovudine [AZT], abacavir [ABC], or tenofovir disoproxil fumarate [TDF] in combination with lamivudine [3TC] or emtricitabine [FTC] in antiretroviral (ARV) treatment-naïve adolescents and children aged greater than or equal to (>=) 6 to less than (<) 18 years.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a Phase II, open-label (all people involved know the identity of the assigned drug) and single arm study.
The study will consist of a screening period of maximum 8 weeks, an initial treatment period of 48 weeks, a post week 48 treatment extension period of 4 years (Cohort 1 only), and a 4 week follow-up (cohort 2 only) period.
Participants who withdraw from the trial on or before the Week 48 visit or subjects with ongoing (serious) adverse events ([S]AEs), laboratory abnormalities, or viral load increase at the last on-treatment visit in the extension, will be seen for a follow-up visit 4 weeks later.
The initial 48-week treatment period will be structured into 2 age Cohorts; Cohort 1 (Aged greater than or equal to [>=] 12 to less than [<] 18 years) and Cohort 2 (Children Aged >= 6 to < 12 years).
The trial is designed to evaluate the steady-state pharmacokinetic (PK) profile (based on intensive PK analysis) and the short-term safety and antiviral activity of rilpivirine (RPV).
Participants will receive RPV 25 milligram (mg), or weight-adjusted dose orally once daily for 240 weeks when administered in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs).
The trial will also evaluate long-term (48 weeks and 240 weeks [Cohort 1]) safety, efficacy, and pharmacokinetics of rilpivirine in combination with the background regimen of 2 NRTIs.
Patients safety will be monitored throughout the study and during the follow up visits.
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chennai, India
-
Mangalore, India
-
-
-
-
-
Nairobi, Kenya
-
-
-
-
-
Bucuresti, Romania
-
-
-
-
-
Bloemfontein, South Africa
-
Dundee, South Africa
-
Middelburg, South Africa
-
Pretoria, South Africa
-
Thabazimbi, South Africa
-
Vosloorus, South Africa
-
-
-
-
-
Bangkok, Thailand
-
Nonthaburi, Thailand
-
-
-
-
-
Entebbe, Uganda
-
Kampala, Uganda
-
-
-
-
-
Kiev, Ukraine
-
-
-
-
New York
-
Syracuse, New York, United States
-
-
Tennessee
-
Memphis, Tennessee, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Has documented human immuno deficiency virus (HIV-1) infection
- Patients who meet the following criteria; a) Cohort 1: Patients Aged greater than or equal to (>=) 12 to less than (<) 18 years, weight is >= 32 kilogram (kg), b) Cohort 2; Aged >= 6 to < 12 years, weight is >= 17 kg
- Must have HIV-1 plasma viral load at screening greater than equal to 500 HIV-1 ribonucleic acid (RNA) copies/mL
- Have not received treatment with a therapeutic HIV vaccine or an HIV drug with the exception of a single dose of nevirapine (NVP) (Cohort 1 and Cohort 2) or up to 6 weeks of zidovudine (AZT) use (Cohort 2 only) prior to screening to prevent mother-to-child transmission (MTCT)
- In the judgment of the investigator, it is appropriate to initiate antiretroviral therapy (ARV) therapy based on a patient's medical condition and taking into account guidelines for the treatment of HIV-1 infection in children of this age group
Exclusion Criteria:
- Any previous use of ARVs with the exception of single dose NVP (Cohort 1 and Cohort 2) or up to 6 weeks of AZT (Cohort 2 only) to prevent MTCT
- Plasma viral load at screening greater than 100,000 HIV-1 RNA copies/mL
- Documented genotypic evidence of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance at screening or from historical data available in the source documents
- Use of disallowed concomitant therapy from 4 weeks prior to the baseline visit
- Patient has any currently active Acquired Immunodeficiency Syndrome (AIDS) defining illness
- Patient has active tuberculosis and/or is being treated for tuberculosis at screening
- Personal history of cardiac disease (including congenital heart disease), or symptomatic arrhythmias, with the exception of sinus arrhythmia; personal history of asymptomatic arrhythmias is excluded if the asymptomatic arrhythmia is clinically significant in the opinion of the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rilpivirine (TMC278)
The patients received rilpivirine with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) as a background regimen in cohort 1 [aged greater than or equal to (> =) 12 to less than (<) 18 years] for up to 240 weeks which is already completed and recruitment closed and will receive this treatment in cohort 2 (children aged > = 6 to < 12 years) for up to 48 weeks.
The NRTIs include zidovudine, abacavir, or tenofovir disoproxil fumarate in combination with lamivudine or emtricitabine.
|
Patients will receive rilpivirine (RPV) tablet 25 milligram dose or an adjusted dose orally once daily in Cohort 1 (adolescents aged >=12 to <18 years) up to 240 weeks.
Patients will receive RPV weight-adjusted dose orally once daily in Cohort 2 (children aged >=6 to <12 years) or 25 mg once daily for up to 48 weeks.
Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral.
The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral.
The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral.
The patients may receive this selected NRTI together with another NRTI once daily for 240 weeks (Cohort 1).
Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral.
The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral.
The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) of Rilpivirine (TMC278) as Measured by Maximum Plasma Concentration (Cmax)
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Pharmacokinetics of Rilpivirine as Measured by Area Under the Plasma Concentration Curve (AUC24)
Time Frame: Up to 48 weeks
|
AUC24 is defined area under the plasma concentration time curve from 0 to 24 hours post dosing of rilpivirine.
|
Up to 48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients with Adverse Events
Time Frame: Up to 244 weeks (Cohort 1 only) (including 4 week follow up visit)
|
Safety measures include adverse events, vital signs, physical examination, hematology, biochemistry and electrocardiogram.
|
Up to 244 weeks (Cohort 1 only) (including 4 week follow up visit)
|
Percentage of Participants With Plasma Human Immunodeficiency Virus - 1 (HIV-1) Ribonucleic Acid (RNA) level Less Than (<) 50 Copies/mL Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Time Frame: Week 48 and Week 240 (Cohort 1 only)
|
Time to loss of virologic response algorithm (TLOVR) requires sustained HIV-1 RNA < 50 copies/mL; confirmed HIV-1 RNA more than or equal to (>=) 50 copies/mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation.
|
Week 48 and Week 240 (Cohort 1 only)
|
Percentage of Participants with Plasma HIV-1 RNA < 50 Copies/mL by FDA Snapshot Approach
Time Frame: Week 48 and Week 240 (Cohort 1 only)
|
FDA Snapshot Approach is based on the last observed viral load data within the Week 48 window: virologic response is defined as HIV-1 RNA <50 copies/mL (observed case); missing HIV-1 RNA is considered as non-response.
|
Week 48 and Week 240 (Cohort 1 only)
|
Evolution of viral genotype and phenotype
Time Frame: Up to 48 Weeks and 240 Weeks (Cohort 1 only)
|
Blood samples will be collected for the determination of HIV-1 genotype and phenotype by the Protocol Virologist based on plasma viral load.
|
Up to 48 Weeks and 240 Weeks (Cohort 1 only)
|
Treatment adherence as measured by the Study Adherence Questionnaire
Time Frame: Up to 48 Weeks and 240 Weeks (Cohort 1 only)
|
This endpoint is measured by Study Adherence Questionnaire for children and teenagers.
The adherence questionnaire should be completed by by the patient.
Ths questionnaire includes questions about the medicine, it's color and dosage.
|
Up to 48 Weeks and 240 Weeks (Cohort 1 only)
|
Change in Cluster of Differentiation (CD4+) cells
Time Frame: Week 48 and Week 240 (Cohort 1 only)
|
Change in the CD4+ cells will evaluate immunologic changes at Week 48 and Week 240 of treatment with rilpivirine.
|
Week 48 and Week 240 (Cohort 1 only)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Janssen Sciences Ireland UC Clinical Trial, Janssen Sciences Ireland UC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 7, 2011
Primary Completion (Actual)
August 16, 2022
Study Completion (Actual)
August 16, 2022
Study Registration Dates
First Submitted
November 26, 2008
First Submitted That Met QC Criteria
November 28, 2008
First Posted (Estimated)
December 1, 2008
Study Record Updates
Last Update Posted (Actual)
August 16, 2023
Last Update Submitted That Met QC Criteria
August 14, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR002677
- TMC278-TiDP38-C213 (Other Identifier: Janssen Sciences Ireland UC)
- 2008-001696-30 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsCompletedHIV-1Burkina Faso, Zambia
-
Hospital Universitari Vall d'Hebron Research InstituteGilead SciencesCompleted
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixaCompleted
-
Gilead SciencesCompleted
-
University of AarhusAarhus University Hospital Skejby; Bandim Health Project; Abbott; Ministry of Health...Completed
-
Tibotec Pharmaceuticals, IrelandCompletedHIV-1United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
-
Tibotec Pharmaceuticals, IrelandCompletedHIV-1United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
-
Mymetics CorporationInstitut Cochin; San Raffaele University Hospital, Italy; Kinesis Pharma B.V.; ... and other collaboratorsCompleted
-
Janssen Pharmaceutica N.V., BelgiumCompleted
Clinical Trials on Rilpivirine
-
Janssen Sciences Ireland UCCompleted
-
Janssen Infectious Diseases BVBACompletedHuman Immunodeficiency Virus Type 1Belgium
-
ViiV HealthcareJanssen Research & Development, LLCRecruitingHIV InfectionsUnited States
-
ViiV HealthcareJanssen Research and DevelopmentActive, not recruitingHIV InfectionsUnited States, Germany, Spain, France, Canada, Korea, Republic of, Italy, South Africa, Australia, Russian Federation, Mexico, Sweden, Argentina
-
ViiV HealthcareJanssen, LPCompletedHIV InfectionsUnited States, Netherlands, Germany, Canada, Australia, Belgium, France, Spain, Ireland, Italy, United Kingdom, Austria, Japan, Switzerland
-
ViiV HealthcareJanssen, LPCompleted
-
University College, LondonLondon School of Hygiene and Tropical Medicine; MRC/UVRI and LSHTM Uganda Research... and other collaboratorsRecruitingHIV Infections | Hiv | HIV-1-infection | Paediatric Human Immunodeficiency Virus InfectionUganda, Zimbabwe, South Africa, Kenya
-
Chiang Mai UniversityUnknownHIV-1-infection | Neurocognitive DysfunctionThailand
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Janssen Sciences Ireland UCViiV HealthcareApproved for marketing